Jun Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Deng has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Dengfeng Zou
School of Pharmacy, Guilin Medical University, Guilin, China
5 shared publications Xiaochuan Zhang
Department of Thoracic Surgery, Kunshan Hospital Affiliated to Jiangsu University, Kunshan 215300, Jiangsu, PR China
3 shared publicationsZhiqiang Chen
School of Pharmacy, Guilin Medical University, Guilin, 541004, Guangxi, P.R. China
3 shared publicationsJianjiao Chen
School of Pharmacy, Guilin Medical University, Guilin, 541004, Guangxi, P. R. China
2 shared publications- Jie Yang
Changshu Inst Technol, Dept Chem & Mat Engn, Jiangsu Key Lab Adv Funct Mat, Changshu 215500, Peoples R China
2 shared publications Xujing Zhang
School of Pharmacy, Guilin Medical University, Guilin 541004, Guangxi, PR China
2 shared publications
Latest Publications
- Open Access
- 26 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 13 (18) , 100610
Birt-Hogg-Dubé syndrome - a rare genetic disorder complicated by pneumothorax: A case report
Birt-Hogg-Dubé (BHD) syndrome is a rare genetic disorder associated with mutations in the BHD gene, which can manifest symptoms at any age, including dermatological and pulmonary complications, as well as renal tumors. This study presents a case of a BHD patient who experienced spontaneous pneumothorax, aiming to enhance the understanding of this syndrome. A 42-year-old female patient presented with left-sided chest pain and tightness lasting three days. Chest computed tomography scans revealed left-sided pneumothorax and multiple pulmonary bullae. Physical examination indicated decreased vocal fremitus and tympanic percussion on the left side. A thorough family history revealed a pattern of pulmonary disorders, including emphysema, spontaneous pneumothorax, and lung cancer among relatives. Genetic testing identified a heterozygous frameshift mutation in the FLCN gene at the 17p11.2 locus. Based on the clinical presentation, imaging findings, family history, and genetic results, the patient was suspected to have BHD syndrome. We present a case of a heterozygous mutation in the FLCN gene in a patient with BHD syndrome, aiming to review the associated clinical characteristics and genetic mechanisms of this condition. This case serves as a reference point to offer insights into the diagnosis of multiple pulmonary cysts and spontaneous pneumothorax of unknown etiology in clinical practice.
- 26 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 13 (18) , 100610
Open AccessBirt-Hogg-Dubé syndrome - a rare genetic disorder complicated by pneumothorax: A case report
Birt-Hogg-Dubé (BHD) syndrome is a rare genetic disorder associated with mutations in the BHD gene, which can manifest symptoms at any age, including dermatological and pulmonary complications, as well as renal tumors. This study presents a case of a BHD patient who experienced spontaneous pneumothorax, aiming to enhance the understanding of this syndrome. A 42-year-old female patient presented with left-sided chest pain and tightness lasting three days. Chest computed tomography scans revealed left-sided pneumothorax and multiple pulmonary bullae. Physical examination indicated decreased vocal fremitus and tympanic percussion on the left side. A thorough family history revealed a pattern of pulmonary disorders, including emphysema, spontaneous pneumothorax, and lung cancer among relatives. Genetic testing identified a heterozygous frameshift mutation in the FLCN gene at the 17p11.2 locus. Based on the clinical presentation, imaging findings, family history, and genetic results, the patient was suspected to have BHD syndrome. We present a case of a heterozygous mutation in the FLCN gene in a patient with BHD syndrome, aiming to review the associated clinical characteristics and genetic mechanisms of this condition. This case serves as a reference point to offer insights into the diagnosis of multiple pulmonary cysts and spontaneous pneumothorax of unknown etiology in clinical practice.
- Open Access
- 9 September 2023
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 4 (20) , 4835-4842
Synthesis of a new photosensitizer for photodynamic and photothermal synergistic cancer therapy
Illustration of synthesis of PDIDPP NPs for photodynamic and photothermal synergistic therapy.
- 9 September 2023
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 4 (20) , 4835-4842
Open AccessSynthesis of a new photosensitizer for photodynamic and photothermal synergistic cancer therapy
Illustration of synthesis of PDIDPP NPs for photodynamic and photothermal synergistic therapy.
- 24 March 2022
- Published by Royal Society of Chemistry (RSC) in Materials Chemistry Frontiers
- Vol. 6 (9) , 1129-1136
Synthesis of a new chlorin photosensitizer for photodynamic therapy against colon cancer
Photodynamic therapy (PDT) shows tremendous potential for the treatment of cancer due to its advantages of non-invasiveness and low systemic toxicity. Porphyrin compounds are potentially translatable photosensitizers with excellent biocompatibility for PDT. In this paper, we prepared a new photosensitizer 2-(1-hexyloxyethyl)-2-devinyl porphin e6 trisodium salt (HCE6) to investigate its anti-colon cancer effects and inhibition mechanism on HT-29 and LoVo human colon cancer cells in vitro and in vivo. The results indicate that HCE6, with high phototoxicity and low dark toxicity, is capable of inhibiting the proliferation and metastasis of human colon tumors.
- 24 March 2022
- Published by Royal Society of Chemistry (RSC) in Materials Chemistry Frontiers
- Vol. 6 (9) , 1129-1136
Synthesis of a new chlorin photosensitizer for photodynamic therapy against colon cancer
Photodynamic therapy (PDT) shows tremendous potential for the treatment of cancer due to its advantages of non-invasiveness and low systemic toxicity. Porphyrin compounds are potentially translatable photosensitizers with excellent biocompatibility for PDT. In this paper, we prepared a new photosensitizer 2-(1-hexyloxyethyl)-2-devinyl porphin e6 trisodium salt (HCE6) to investigate its anti-colon cancer effects and inhibition mechanism on HT-29 and LoVo human colon cancer cells in vitro and in vivo. The results indicate that HCE6, with high phototoxicity and low dark toxicity, is capable of inhibiting the proliferation and metastasis of human colon tumors.
- 1 February 2021
- Published by Royal Society of Chemistry (RSC) in Materials Chemistry Frontiers
- Vol. 5 (6) , 2694-2701
Designing a lysosome targeting nanomedicine for pH-triggered enhanced phototheranostics
Developing intelligent photosensitizers (PSs) responding to the tumor microenvironment (TME) to maximize the therapeutic efficacy and minimize side effects is a major problem for tumor phototherapy. In this paper, a dimethylamino (–NMe2)-functionalized boron dipyrromethene (Bodipy) derivative, namely, (E)-3-(4-(dimethylamino)styryl)-5,5-difluoro-2,8-diiodo-1,7,9-trimethyl-10-phenyl-5H-di-pyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinin-4-ium-5-uide (BDPIN) has been designed and synthesized by a Knoevenagel condensation reaction. BDPIN has a high singlet oxygen quantum yield (1O2 QY) of 74.8% in dichloromethane, and retains high 1O2 generation ability when nanoprecipitated in water with DSPE-PEG. For the synergistic therapy (photothermal conversion efficiency ∼28.6%), BDPIN NPs show a low half maximum inhibitory concentration (IC50) of 4.4 μg mL−1 towards human cervical cancer cells (HeLa). However, the dark toxicity of BDPIN NPs is almost negligible even at high concentrations. NPs with lysosome targeting ability can be triggered by the low acidity for enhanced phototherapy. Furthermore, an in vivo study demonstrates that NPs are able to inhibit tumor proliferation with laser irradiation, while causing no damage to normal tissues, suggesting the high phototoxicity, low dark toxicity and outstanding biosafety of BDPIN NPs. Results provide an approach for synthesizing nanomedicine in pH-activated enhanced phototheranostics.
- 1 February 2021
- Published by Royal Society of Chemistry (RSC) in Materials Chemistry Frontiers
- Vol. 5 (6) , 2694-2701
Designing a lysosome targeting nanomedicine for pH-triggered enhanced phototheranostics
Developing intelligent photosensitizers (PSs) responding to the tumor microenvironment (TME) to maximize the therapeutic efficacy and minimize side effects is a major problem for tumor phototherapy. In this paper, a dimethylamino (–NMe2)-functionalized boron dipyrromethene (Bodipy) derivative, namely, (E)-3-(4-(dimethylamino)styryl)-5,5-difluoro-2,8-diiodo-1,7,9-trimethyl-10-phenyl-5H-di-pyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinin-4-ium-5-uide (BDPIN) has been designed and synthesized by a Knoevenagel condensation reaction. BDPIN has a high singlet oxygen quantum yield (1O2 QY) of 74.8% in dichloromethane, and retains high 1O2 generation ability when nanoprecipitated in water with DSPE-PEG. For the synergistic therapy (photothermal conversion efficiency ∼28.6%), BDPIN NPs show a low half maximum inhibitory concentration (IC50) of 4.4 μg mL−1 towards human cervical cancer cells (HeLa). However, the dark toxicity of BDPIN NPs is almost negligible even at high concentrations. NPs with lysosome targeting ability can be triggered by the low acidity for enhanced phototherapy. Furthermore, an in vivo study demonstrates that NPs are able to inhibit tumor proliferation with laser irradiation, while causing no damage to normal tissues, suggesting the high phototoxicity, low dark toxicity and outstanding biosafety of BDPIN NPs. Results provide an approach for synthesizing nanomedicine in pH-activated enhanced phototheranostics.
- 1 November 2020
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 212, 111233
Two Ru(II) compounds with aggregation induced emission as promising photosensitizers for photodynamic therapy
- 1 November 2020
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 212, 111233
Two Ru(II) compounds with aggregation induced emission as promising photosensitizers for photodynamic therapy
- 1 November 2020
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 212, 111236
Boosting type I process of Ru(II) compounds by changing tetrazole ligand for enhanced photodynamic therapy against lung cancer
- 1 November 2020
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 212, 111236
Boosting type I process of Ru(II) compounds by changing tetrazole ligand for enhanced photodynamic therapy against lung cancer
- 28 October 2020
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 8 (47) , 10764-10769
A carbazole functionalized semiconducting compound as a heavy atom free photosensitizer for phototherapy against lung cancer
Semiconducting compounds with high photostability and excellent photothermal ability are potential candidates for phototheranostics. In this paper, the heavy atom free compound 3,6-bis(5-(4-(9H-carbazol-9-yl)phenyl)furan-2-yl)-2,5-bis(2-octyldodecyl)pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione (denoted as DPPCz) has been designed and synthesized through a C–H activation coupling reaction. DPPCz has a high singlet oxygen quantum yield (1O2 QY) of 40.3% in DCM. In addition, DPPCz NPs obtained by nanoprecipitation exhibit a high photothermal conversion efficiency (48.2%) in water. DPPCz NPs have a low half inhibitory concentration (IC50) of 7.1 μg mL−1 towards human lung cancer cells (A549) with irradiation while the dark toxicity is almost negligible even at high concentrations. Furthermore, in vivo photothermal imaging guided study demonstrates that these NPs are able to inhibit tumor growth with the help of laser. The H&E stained pictures of the normal tissues indicate the biosafety of DPPCz NPs in that no obvious damage was observed. Our results demonstrate that DPPCz NPs are potential semiconducting photosensitizers for phototheranostics.
- 28 October 2020
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 8 (47) , 10764-10769
A carbazole functionalized semiconducting compound as a heavy atom free photosensitizer for phototherapy against lung cancer
Semiconducting compounds with high photostability and excellent photothermal ability are potential candidates for phototheranostics. In this paper, the heavy atom free compound 3,6-bis(5-(4-(9H-carbazol-9-yl)phenyl)furan-2-yl)-2,5-bis(2-octyldodecyl)pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione (denoted as DPPCz) has been designed and synthesized through a C–H activation coupling reaction. DPPCz has a high singlet oxygen quantum yield (1O2 QY) of 40.3% in DCM. In addition, DPPCz NPs obtained by nanoprecipitation exhibit a high photothermal conversion efficiency (48.2%) in water. DPPCz NPs have a low half inhibitory concentration (IC50) of 7.1 μg mL−1 towards human lung cancer cells (A549) with irradiation while the dark toxicity is almost negligible even at high concentrations. Furthermore, in vivo photothermal imaging guided study demonstrates that these NPs are able to inhibit tumor growth with the help of laser. The H&E stained pictures of the normal tissues indicate the biosafety of DPPCz NPs in that no obvious damage was observed. Our results demonstrate that DPPCz NPs are potential semiconducting photosensitizers for phototheranostics.
- Open Access
- 15 April 2016
- Published by Nipissing University Library in The Canadian Journal of Action Research
- Vol. 17 (1) , 83-85
Phillips, D. K., & Carr, K. (2014). Becoming a teacher through action research (3rd ed.). Oxford: Routledge.
This book is especially written for preservice teachers by two professors in Education. It intends to navigate them through an action research journey, from understanding action research, investigating data, designing research method, collecting data, analyzing and interpreting data, to communicating the results to others. The purpose is to transform a novice teacher and researcher to an expert in his/her teaching area. In the introduction section, Phillips and Carr view trustworthy action research as "a process", "a way of thinking", and "a way of practicing teaching" in which the teacher researcher is the subject of the study. There should be four key elements: 1) a strong sense of connection between the teacher, the context, study design and literature base; 2) quality data; 3) evidence of self-reflexivity; and 4) meaningful results. A figure is included to display the whole process of becoming a teacher through action research.
- 15 April 2016
- Published by Nipissing University Library in The Canadian Journal of Action Research
- Vol. 17 (1) , 83-85
Open AccessPhillips, D. K., & Carr, K. (2014). Becoming a teacher through action research (3rd ed.). Oxford: Routledge.
This book is especially written for preservice teachers by two professors in Education. It intends to navigate them through an action research journey, from understanding action research, investigating data, designing research method, collecting data, analyzing and interpreting data, to communicating the results to others. The purpose is to transform a novice teacher and researcher to an expert in his/her teaching area. In the introduction section, Phillips and Carr view trustworthy action research as "a process", "a way of thinking", and "a way of practicing teaching" in which the teacher researcher is the subject of the study. There should be four key elements: 1) a strong sense of connection between the teacher, the context, study design and literature base; 2) quality data; 3) evidence of self-reflexivity; and 4) meaningful results. A figure is included to display the whole process of becoming a teacher through action research.